🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Published 09/26/2024, 11:39 AM
Updated 09/26/2024, 03:57 PM
© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
VRTX
-
PFE
-
BLUE
-
AGIO
-
FULC
-

By Kashish Tandon and Christy Santhosh

(Reuters) - Pfizer (NYSE:PFE)'s decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Oxbryta, one of at least six treatments for the disease, is mostly used in patients with mild-to-moderate symptoms. The drug received accelerated approved in the U.S. in 2019, requiring further trials to confirm the benefits.

In July, the European Medicines Agency posted online concerns about deaths in two of those trials. The regulator, after a meeting on Thursday to discuss the data, said that it had serious concerns about the safety. It recommended an immediate suspension of its authorization.

The U.S. Food and Drug Administration said it was conducting a safety review of postmarketing clinical data for the drug, and will also review real world registry studies. After the review it will communicate any additional findings, if necessary.

At least three Wall Street brokerages said the withdrawal could create an immediate need to accelerate trials of rival drugs for the inherited condition, including Agios Pharmaceuticals' mitapivat and Fulcrum Therapeutics (NASDAQ:FULC)' pociredir.

Enrollment in an early-stage trial has been a hurdle for Fulcrum, said analysts at Leerink.

In case of Agios, it could create pressure on regulators to speed up the review, Piper Sandler analysts said.

If mitapivat shows benefit in reducing the painful episodes that mark the disease, "we anticipate this will enable an easier regulatory review, especially now considering the greater demands from patients who can no longer access Oxbryta," said Piper Sandler's Christopher J. Raymond.

Shares of Agios rose 4% before reversing gains, while Fulcrum jumped over 17% on Thursday.

Two recently approved gene therapies - bluebird bio's Lyfgenia and Vertex Pharmaceuticals (NASDAQ:VRTX)' and partner CRISPR Therapeutics' Casgevy - are reserved for people with severe form of the disease.

The removal of Oxbryta likely leaves the vast majority of patients, who have mild-moderate symptoms, relying on chemotherapy medicine hydroxyurea, said Stifel analyst Dae Gon Ha on Thursday.

Sickle cell disease affects an estimated 100,000 people in the U.S., most of whom are Black.

The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla. Investors have punished the company as it navigates sharply dropping sales for its COVID vaccines and drugs, a weaker-than-hoped launch of its respiratory syncytial virus (RSV) vaccine and disappointing clinical data for an obesity pill it was developing.

Pfizer's shares were marginally down on Thursday. The stock is trading at around half its pandemic highs.

© Reuters. FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics (NASDAQ:GBT) in 2022, one of a number of deals bankrolled by the pandemic-era windfall. It also picked up two other experimental sickle cell treatments, both of which remain in clinical trials, according to Pfizer's website.

In patients with the disease, red blood cells become sickle or crescent shaped and can cause strokes, organ damage and early death, as well as debilitating pain crises.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.